Answers are grounded in this paper and cite their sources.
Introduction The United States cannabidiol (CBD) market is growing substantially; however, questions remain regarding CBD’s pharmacokinetics, metabolism, and neurological effects. This work describes the development of a novel imaging mass spectrometry method to detect CBD and its major metabolites, 7-hydroxy-cannabidiol (CBD-OH) and 7-carboxy-cannabidiol (CBD-COOH), and its subsequent application to biological tissue. Methods A matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) method utilizing FMP-10 derivatization was developed and validated prior to biological application. FMP-10 selectively targets primary and secondary amines and phenolic hydroxyl groups present in CBD and its metabolites, improving ionization efficiency and enabling their detection. Validation was performed by spotting serial dilutions of CBD, CBD-OH, and CBD-COOH standards on and under control rat brain tissue sections to confirm derivatization efficiency and establish limits of detection, with metabolite identities confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The method was then applied to brain tissue from a postnatal day 21 (PND 21) Sprague Dawley rat from a 300 mg/kg/day dose-ranging group. Following MALDI-MSI analysis, the same tissue sections underwent photocleavable mass tag immunohistochemistry (PC-MT IHC) using a neurology-specific 6-plex antibody panel. Results FMP-10 derivatization enabled successful detection of CBD ( m/z 582.3370), CBD-OH ( m/z 598.3312), and CBD-COOH ( m/z 612.3111). CBD signal was detected in the brain tissue of the treated animal. Multiple neurotransmitters were identified based on accurate mass measurements, including double-derivatized dopamine, norepinephrine, and epinephrine. PC-MT IHC successfully identified key cellular markers including neurofilament light (NF-L), myelin basic protein (MBP), glial fibrillary acidic protein (GFAP), and glucose transporter type 1 (GLUT1). Discussion To our knowledge, this represents the first application of FMP-10 derivatization for the detection of CBD and its metabolites in biological tissue using mass spectrometry imaging. The integrated MALDI-MSI and PC-MT IHC workflow established here provides a proof-of-concept platform for spatially resolving drug distribution alongside neurobiological markers and endogenous neurotransmitters within a single imaging experiment. This approach has broad potential for advancing cannabinoid safety research and supporting evidence-based regulatory evaluation of CBD-containing products.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: